SAN DIEGO, Sept. 07, 2022 (GLOBE NEWSWIRE) — Shareholder Rights Law Firm Johnson Fistula, LLP announces that a class action lawsuit has been filed on behalf of investors Molecular Partners AG (“Molecular Partners” or the “Company”) CLOUD. The Class Action is being brought on behalf of shareholders who have purchased securities of Molecular Partners pursuant to the and/or understandable offering documentation (defined below) issued in connection with the Company’s initial public offering on or about June 16, 2021 (the “IPO”) became. ; and/or (b) securities of Molecular Partners between June 16, 2021 and April 26, 2022, both dates inclusive (the “Collection Period”). Investors are hereby notified that they have until September 12, 2022 to request the court to appear as lead plaintiff in this lawsuit.

What actions can I take at this time? If you have suffered a loss and would like to learn more about whether you are a Lead Plaintiff, please contact Jim Baker ([email protected]) via email or phone at 619-814-4471. When emailing, please include your phone number.

To participate in this promotion you can click on the following link or copy and paste it into a browser:

https://www.johnsonfistel.com/investigations/molecular-partners-mol-class-action

There are no costs or obligations for you.

The complaint alleges that the offering documents were negligently prepared and, as a result, contained untrue statements about material facts or failed to state other facts necessary for the statements made not to be misleading and that they were not in accordance with the Rules and rules for their creation have been drawn up . In addition, the lawsuit alleges that the defendants made materially false and misleading statements about the Company’s business, operations and prospects throughout the class period. In particular, the Offering Documents and the Defendants have made false and/or misleading statements and/or failed to disclose the following: (i) ensovibep was less effective in treating COVID-19 than the Defendants wanted investors to believe; (ii) Accordingly, the FDA was…